PHARMAC is pleased to announce the approval of a proposal for abiraterone acetate (Zytiga), methylphenidate hydrochloride extended release (Concerta), topiramate (Topamax) and epoetin alfa (Eprex). The proposal was the subject of a consultation letter dated 26 February 2015.

In summary, the effect of the decision is that:

• From 1 May 2015 abiraterone acetate (Zytiga) 250 mg tablets will be funded, subject to Special Authority criteria, for patients with metastatic castration resistant prostate cancer that is resistant to androgen deprivation therapy (ADT)
• From 1 May 2015 two new presentations of epoetin alfa (Eprex) – Inj 8,000 iu in 0.8 mL syringe and Inj 40,000 iu in 1 mL syringe will be funded
• From 1 July 2015 the net costs of methylphenidate hydrochloride extended-release tablets (Concerta) and topiramate tablets and sprinkle capsules (Topamax) will be reduced

For more details, go to: http://www.pharmac.health.nz/news/notification-2015-04-08-various/